EGFR inhibitory monoclonal antibodies and EGFR tyrosine kinase inhibitors have distinct effects on the keratinocyte innate immune response.
Br J Dermatol 2017 Mar 10. Epub 2017 Mar 10.
Department of Dermatology, Nara Medical University, Nara, Japan.
Epidermal growth factor receptor inhibitors (EGFRIs) are a well-established targeted therapy for several cancers. Two categories of EGFRIs are known, EGFR tyrosine kinase inhibitors (EGFR-TKIs) and EGFR monoclonal antibodies (EGFR mAbs). These EGFRIs frequently cause cutaneous adverse effects, such as papulo-pustular eruptions, xerosis and chronic paronychia. Read More